

- 25 8. Yale Center for Systems and Engineering Immunology and Department of Immunobiology,
- 26 Yale University School of Medicine, New Haven, CT 06520
- 27 9. Department of Ecology and Evolution, University of Chicago, Chicago, IL 60637
- 28

29 **Corresponding author:**

- 30 Prof. Benjamin J. Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The
- 31 University of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong
- 32 Tel: +852 3917 6711; Email: bcowling@hku.hk
- 33
- 34 Word count (abstract): 312
- 35 Word count (main text): 3,473
- 36 Running head: Antibody responses after repeated influenza vaccination
- 37 Clinicaltrials.gov: NCT04576377
- 38
- 39

40 **ABSTRACT**

- 65 providing an opportunity to explore antigenic distances between those strains in humans in
- 66 subsequent years.
- 67
- 68 Key words: influenza; vaccination; immunogenicity; antibody
- 69

70 **INTRODUCTION**

83

84 Enhanced influenza vaccines, including the recombinant hemagglutinin vaccine Flublok 85 (Sanofi Pasteur), stimulate stronger immune responses and may be able to overcome repeat 86 vaccination effects. The Flublok vaccine has two major differences with the standard egg-87 grown inactivated influenza vaccine [10, 16, 17]. First, because eggs are not used in the 88 production process for Flublok, the antigens included in the vaccine are more similar to 89 circulating viruses, circumventing the issue of egg-adapted mutations in the hemagglutinin 90 (HA) protein that can lead to antigenic mismatch [10, 18]. Second, it includes three times 91 more HA antigen than standard-dose vaccines and can therefore generate a stronger, more 92 HA-specific humoral immune response [10, 11]. Flublok has been approved by the Food and 93 Drug Administration for use in the United States in all adults ≥18 years of age since October 94 2014 [19]. Evidence from randomized trials have shown improved immunogenicity and

- 96 influenza vaccine in adults ≥18 years [20].
- 97

98 We designed a randomized controlled trial to explore immune responses to first-time or 99 repeated influenza vaccination with the Flublok vaccine, with a particular interest in the 100 possible occurrence of repeat vaccination effects.

101

102 **METHODS**

103 *Study design*

104 This study is a randomized controlled trial in adults 18-45 years of age at enrolment

105 (Clinicaltrials.gov: NCT04576377). Participants were enrolled from the general community

106 in Hong Kong, with study advertisements distributed via institutions (such as schools and

107 universities), organizations (such as professional associations), and local community centers,

108 and through mass promotion efforts including mass mailing to residential estates,

109 advertisements in newspapers and public transport, social media platforms (such as

110 Facebook), bulk emails, and invitation to and referrals from members of previous studies.

111 Individuals were eligible to participate if they were between 18 and 45 years of age, capable

112 of providing informed consent, and intending to reside in Hong Kong for at least the next two

113 years. Potential participants were excluded if they had been vaccinated against influenza in

114 the preceding 24 months, if they were included in a priority group for influenza vaccination

115 (e.g. healthcare worker, pregnant woman), if they had a diagnosed immunosuppressive

- 116 condition or were taking immunosuppressive medication, or if they had severe allergies or
- 117 bleeding conditions that contraindicated intramuscular influenza vaccination.
- 118

143 randomization scheme. Other than the nurse who conducted the injections, all other study 144 staff were blinded to the study intervention.

186 *Laboratory analysis*

187 Blood samples were collected in tubes for clotted blood, stored in a refrigerated container at

188 2-8°C immediately and delivered to the laboratory within two days for further processing.

- 189 Serum specimens were aliquoted and stored at -80°C prior to subsequent testing. Serum
- 190 samples were treated with receptor destroying enzyme (RDE) and tested by HAI against the
- 191 influenza A(H1N1) and B vaccine strains using a standard protocol [26]. For influenza
- 192 A(H1N1), the vaccine strains were A/Hawaii/70/2019 in 2020/21 (GISAID Accession #

212

213 To estimate total binding antibody of specific IgG responses, Enzyme Linked Immunosorbent 214 Assays (ELISAs) were performed with recombinant HA (rHA) of the A(H1N1) vaccine

- 215 strains A/Hawaii/70/2019 in 2020/21 and A/Wisconsin/588/2019, and the A(H3N2) vaccine
- 216 strains A/Minnesota/41/2019 and A/Tasmania/503/2020 (Appendix Table 1). The HA stalk

219

220 *Sample size justification*

221 We aimed to enroll 820 participants into our study. This would permit us to have a sample 222 size of at least 100 participants in each of the five groups at the fourth year of follow-up, 223 allowing for an anticipated drop-out rate of 15% per year without replacement. Most of our 224 outcome measures, including both of our primary outcome measures, are based on geometric 225 mean antibody titers. In year 2, with a target sample size of 139 in each group, we expected 226 to have 80% power to identify 1.6-fold differences in GMT between groups, assuming a 227 standard deviation of $log_2(GMT)$ of 1.8. However, due to disruption in study activities during 228 the COVID-19 pandemic we were unable to reach our target sample size, and as a 229 consequence we updated the protocol to include enrolment of an additional cohort of 530 230 participants starting in 2021/22 with a similar trial design, with participants randomized 231 across four groups instead of five, and receiving four annual doses of vaccination/placebo as 232 part of the study instead of five. Results from the second cohort with participant enrolment in 233 2021/22, named DRIVE II, will be reported in due course. For consistency, the present cohort 234 with participant enrolment in 2020/21 is named DRIVE I.

235

236 *Statistical analysis*

237 We assessed the proportion of participants who achieved a 4-fold or greater rise in antibody 238 titre against each of the vaccine strains at 30 days, and compared these proportions between 239 the vaccine-vaccine, placebo-vaccine and placebo-placebo groups using Fisher exact tests, 240 pooling the three placebo-placebo groups together. We estimated GMT ratios versus the 241 placebo group at day 30 of year 2 and compared them between first-time vaccines and repeat

242 vaccinees using t-tests on the log-transformed GMT ratios. Confidence intervals were 243 estimated using t distributions. All analyses were conducted in R version 4.2.1 (R Foundation 244 for Statistical Computing, Vienna, Austria). Data and R syntax will be made available after 245 publication.

246

247 **RESULTS**

248 From 23 October 2020 through 11 March 2021, 447 individuals were enrolled and received

249 influenza vaccination or placebo according to the randomization scheme, with 88 to 91

250 individuals in each arm (Figure 1). The median age of participants was 31 years, and 54%

251 were male, with similar characteristics across the five arms (Table 1). None of the

252 participants reported receiving influenza vaccination in the two years prior to the start of the

253 trial, and only 12% reported ever previously receiving influenza vaccination. We randomly

254 selected for laboratory analysis a subset of 15 participants from groups 1-3 (who received

255 placebo in both years), 40 participants from group 4 (placebo followed by vaccination), and

256 40 participants from group 5 (vaccination in both years), and noted similar characteristics in

257 this subset to the overall participants (Appendix Table 2).

258

259 Antibody titers increased between days 0 and 30 against each of the vaccine strains, with 260 greater fold increases for first-time vaccinees compared to repeat vaccinees, while the repeat 261 vaccinees had higher antibody titers prior to vaccination in year 2 (Figure 2). At day 30 of 262 year 2, the GMTs were similar in the first-time vaccinees and repeat vaccinees (groups 4 and 263 5, respectively) for each strain analyzed (Appendix Table 4). While there were statistically 264 significant reductions in the proportion achieving a four-fold greater rise in antibody titer for 265 the repeat vaccinees in year 2 for A(H1N1), B/Victoria and B/Yamagata, there were no

266 statistically significant differences in GMTs at day 30 or the proportions with antibody titers ²⁶⁷≥40 at day 30 for any of the strains (Table 2).

268

291 first-time vaccinees had slightly higher absolute post-vaccination titers to the vaccine strain 292 (A/Cambodia/e0826360/2020) compared to individuals vaccinated with A/Hong 293 Kong/45/2019 the previous year (titers of 45.6 vs. 34.7), showing the strain update still led 294 to increased titers to the intended strain. 295 296 That first-time vaccinees in year 2 mounted higher titers to the prior year's influenza A 297 vaccine strains than to the current vaccine strains might reflect a strong influence of prior 298 immunity, but it could also reflect differences in receptor avidity between the strains. Viruses 299 that bind to cells with lower avidity are more easily neutralized by antibodies compared to 300 viruses that bind with higher avidity, irrespective of antigenic differences [30]. To address 301 this, we measured total HA-specific IgG antibody responses by ELISAs which are not 302 affected by differences in viral receptor binding avidities, to measure antibody binding to the 303 influenza A(H1N1) and A(H3N2) vaccine strains, with results shown in Figure 3 and Table 3. 304 We found that the year 2, geometric mean day 30 antibody levels to the current vaccine strain 305 were similar to or slightly higher than those to the previous vaccine strain in first-time 306 vaccinees, suggesting no disproportionate boosting of prior immunity targeting past strains. 307 That there were no statistically significant differences in the geometric mean post-vaccination 308 antibody levels measured by ELISA between first-time vaccinees in years 1 and 2 suggests 309 the previously reported low HAI and FRNT titers to A/Wisconsin/588/2019 and 310 A/Cambodia/e0826360/2020 thus likely arise from differences in the receptor avidity. The 311 antigenic distances implied by the ELISA data are also smaller and do not show the same 312 asymmetry as before. For instance, the amount of antibody reactive to A/Wisconsin/588/2019 313 after vaccination with A/Hawaii/70/2019 (group 5, year 1, day 30) was similar to the amount

314 of antibody reactive to A/Hawaii/70/2019 after vaccination with A/Wisconsin/588/2019

315 (group 4, year 2, day 30) (Table 3). Finally, consistent with the data from the HAI and FRNT

318

319 **DISCUSSION**

321 repeat vaccination for influenza A(H1N1), B/Victoria and B/Yamagata (Figure 2). However,

322 post-vaccination GMTs were similar in repeat vaccinees and first-time vaccinees, indicating

323 that these reduced responses likely would not hinder overall protection assuming that the

324 post-vaccination HAI titer correlates with protection for Flublok [31]. During the study

325 period, public health measures used to contain COVID-19 also prevented the community

326 circulation of influenza [23], and our analysis of antibody titers is therefore unaffected by any

327 potential differences in incidence of influenza virus infections in vaccine versus placebo

328 recipients in the first year of the study that could have occurred if influenza had been

329 circulating.

330

332 vaccination GMTs to A(H3N2) measured by FRNT (Figure 2), indicative of similar levels of

333 clinical protection. However, there was no substantial blunting of the fold rises to A(H3N2)

334 in repeat vaccinees. Both groups started with low GMTs to A/Cambodia/e0826360/2020

335 (H3N2) in year 2 and increased those GMTs approximately 4-fold by 30 days post-

336 vaccination (Figure 2, Appendix Table 4). Our ELISA analyses measuring direct antibody

337 binding suggest that the observed differences in HAI and FRNT titers between groups could

338 be due to differences in receptor binding avidities of the viral strains used in our studies.

339

365 other epitopes that are poorly measured by HAI. Understanding the roles of these factors is an 366 important area for further work [32].

367

- 368 In conclusion, our randomized clinical trial of repeat influenza vaccination has found that
- 369 repeat vaccination can be associated with reduced fold changes in antibody titers, but our
- 370 preliminary results show no evidence of reduced post-vaccination mean titers, consistent with
- 371 similar levels of protection after vaccination regardless of vaccination history. The apparently
- 372 low immunogenicity of influenza A vaccine strains in 2021/22 relative to the prior year may
- 373 reflect increases in receptor avidity of updated vaccine strains and deserves further study.

374

376 **ACKNOWLEDGMENTS**

- 377 The authors thank Suk Yee Chan, Tin Kin Chau, Trushar Jeevan, Pat Kaewpreedee, Ida Lam,
- 378 Erica Lau, Kelly Lee, Maggie Lo, Charlie Man, Tiffany Ng, Yammy Ng, Yvonne Ng, Eunice
- 379 Shiu, Lewis Siu, Tiffany Tavares, Ivan Tsai, Lilly Wang, Angel Wong, Irene Wong, Miyuki
- 380 Wong, Phebe Yeung, and Zoe Xiao for technical support, and Julie Au and Ada Lee for
- 381 administrative support.

382

383 **FUNDING**

- 384 This project was supported by federal funds from the National Institute of Allergy and
- 385 Infectious Diseases, National Institutes of Health, Department of Health and Human Services
- 386 (grant no. U01 AI153700 and contract nos. 75N93021C00015 and 75N93021C00016), and
- 387 the Theme-based Research Scheme (Project No. T11-712/19-N) of the Research Grants
- 388 Council of the Hong Kong SAR Government. BJC is supported by an RGC Senior Research
- 389 Fellowship (grant number: HKU SRFS2021-7S03).

390

391 **POTENTIAL CONFLICTS OF INTEREST**

- 392 B.J.C. consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna,
- 393 Novavax, Pfizer, Roche and Sanofi Pasteur. S.C. has consulted for Seqirus. S.E.H. is a co-
- 394 inventor on patents that describe the use of nucleoside-modified mRNA as a vaccine platform.
- 395 S.E.H reports receiving consulting fees from Sanofi, Pfizer, Lumen, Novavax, and Merck.
- 396 The authors report no other potential conflicts of interest.

398 **REFERENCES**

- 399 1. Chung JR, Rolfes MA, Flannery B, et al. Effects of Influenza Vaccination in the United
- 400 States During the 2018-2019 Influenza Season. Clin Infect Dis **2020**; 71:e368-e76.
- 401 2. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by
- 402 subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect
- 403 Dis **2016**; 16:942-51.
- 404 3. McLean HQ, Thompson MG, Sundaram ME, et al. Impact of Repeated Vaccination on
- 405 Vaccine Effectiveness Against Influenza A(H3N2) and B During 8 Seasons. Clin Infect Dis
- 406 **2014**; 59:1375-85.
- 407 4. Skowronski DM, Chambers C, Sabaiduc S, et al. A Perfect Storm: Impact of Genomic
- 408 Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-
- 409 2015 Season. Clin Infect Dis **2016**; 63:21-32.
- 410 5. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G.
- 411 Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert
- 412 Rev Vaccines **2017**; 16:1-14.
- 413 6. Ramsay LC, Buchan SA, Stirling RG, et al. The impact of repeated vaccination on
- 414 influenza vaccine effectiveness: a systematic review and meta-analysis. BMC Med **2019**;
- 415 17:9.
- 416 7. Jones-Gray E, Robinson EJ, Kucharski AJ, Fox A, Sullivan SG. Does repeated influenza
- 417 vaccination attenuate effectiveness? A systematic review and meta-analysis. Lancet Respir
- 418 Med **2023**; 11:27-44.
- 419 8. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP.
- 420 Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-
- 421 Dose Inactivated Influenza Vaccine in Older Adults. Clin Infect Dis **2016**; 62:1092-9.

- 422 9. Thompson MG, Naleway A, Fry AM, et al. Effects of repeated annual inactivated
- 423 influenza vaccination among healthcare personnel on serum hemagglutinin inhibition
- 424 antibody response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. Vaccine **2016**;
- 425 34:981-8.
- 426 10. Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a
- 427 glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.
- 428 Proc Natl Acad Sci U S A **2017**; 114:12578-83.
- 429 11. Gouma S, Zost SJ, Parkhouse K, et al. Comparison of Human H3N2 Antibody Responses
- 430 Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines
- 431 During the 2017-2018 Season. Clin Infect Dis **2020**; 71:1447-53.
- 432 12. Leung VKY, Fox A, Carolan LA, et al. Impact of prior vaccination on antibody response
- 433 and influenza-like illness among Australian healthcare workers after influenza vaccination in
- 434 2016. Vaccine **2021**; 39:3270-8.
- 435 13. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual
- 436 influenza vaccination. PNAS **1999**; 96:14001-6.
- 437 14. Skowronski DM, Chambers C, De Serres G, et al. Serial Vaccination and the Antigenic
- 438 Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2)
- 439 Epidemics in Canada, 2010-2011 to 2014-2015. J Infect Dis **2017**; 215:1059-99.
- 440 15. Monto AS, Malosh RE, Petrie JG, Martin ET. The Doctrine of Original Antigenic Sin:
- 441 Separating Good From Evil. J Infect Dis **2017**; 215:1782-8.
- 442 16. Harding AT, Heaton NS. Efforts to Improve the Seasonal Influenza Vaccine. Vaccines
- 443 (Basel) **2018**; 6.
- 444 17. Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza
- 445 vaccine. Influenza Other Respir Viruses **2008**; 2:211-9.

- 446 18. Yang LP. Recombinant trivalent influenza vaccine (flublok((R))): a review of its use in
- 447 the prevention of seasonal influenza in adults. Drugs **2013**; 73:1357-66.
- 448 19. Izikson R, Leffell DJ, Bock SA, et al. Randomized comparison of the safety of
- 449 Flublok((R)) versus licensed inactivated influenza vaccine in healthy, medically stable adults
- 450 >/= 50 years of age. Vaccine **2015**; 33:6622-8.
- 451 20. Cox MM, Izikson R, Post P, Dunkle L. Safety, efficacy, and immunogenicity of Flublok
- 452 in the prevention of seasonal influenza in adults. Ther Adv Vaccines **2015**; 3:97-108.
- 453 21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
- 454 data capture (REDCap)--a metadata-driven methodology and workflow process for providing
- 455 translational research informatics support. J Biomed Inform **2009**; 42:377-81.
- 456 22. Allen JD, Ross TM. H3N2 influenza viruses in humans: Viral mechanisms, evolution,
- 457 and evaluation. Hum Vaccin Immunother **2018**; 14:1840-7.
- 458 23. Xiong W, Cowling BJ, Tsang TK. Influenza Resurgence after Relaxation of Public
- 459 Health and Social Measures, Hong Kong, 2023. Emerg Infect Dis **2023**; 29:2556-9.
- 460 24. Mak GCK, Lau SSY, Lam ETK, Ng KHL, Chan RCW. Domination of influenza vaccine
- 461 virus strains in Hong Kong, 2021. Influenza Other Respir Viruses **2022**; 16:1191-3.
- 462 25. Mak GCK, Lau SSY, Wong KKY, Lau AWL, Hung DLL. Low prevalence of seasonal
- 463 influenza viruses in Hong Kong, 2022. Influenza Other Respir Viruses **2023**; 17:e13123.
- 464 26. WHO Global Influenza Surveillance Network. WHO global influenza surveillance
- 465 network: Manual for the laboratory diagnosis and virological surveillance of influenza.
- 466 Available at:
- 467 https://iris.who.int/bitstream/handle/10665/44518/9789241548090_eng.pdf?sequence=1.
- 468 27. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of
- 469 Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014-2015
- 470 Influenza Season. Cell Rep **2015**; 12:1-6.

- 471 28. Gouma S, Weirick M, Hensley SE. Antigenic assessment of the H3N2 component of the
- 472 2019-2020 Northern Hemisphere influenza vaccine. Nat Commun **2020**; 11:2445.
- 473 29. Bolton MJ, Santos JJS, Arevalo CP, et al. IgG3 subclass antibodies recognize
- 474 antigenically drifted influenza viruses and SARS-CoV-2 variants through efficient bivalent
- 475 binding. Proc Natl Acad Sci U S A **2023**; 120:e2216521120.
- 476 30. Fazekas S, Groth S. Antigenic, Adaptive and Adsorptive Variants of the Influenza a
- 477 Hemagglutinin. In: Laver, W.G., Bachmayer, H., Weil, R. (eds) The Influenza Virus
- 478 Hemagglutinin. Topics in Infectious Diseases, vol 3. Springer, Vienna.
- 479 https://doi.org/10.1007/978-3-7091-4130-4 3. In: Laver WG, Bachmayer H, Weil R, eds.
- 480 The Influenza Virus Hemagglutinin Topics in Infectious Diseases, vol 3. Vienna: Springer,
- 481 **1978**.
- 482 31. Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant
- 483 hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized,
- 484 placebo-controlled trial. Vaccine **2011**; 29:7733-9.
- 485 32. Loes AN, Tarabi RAL, Huddleston J, et al. High-throughput sequencing-based
- 486 neutralization assay reveals how repeated vaccinations impact titers to recent human H1N1
- 487 influenza strains. bioRxiv **2024**:2024.03.08.584176.

488

490 **FIGURE LEGENDS**

- 491 Figure 1. Study flow chart showing participant enrolment into the study, randomization into
- 492 five groups, interventions received, and follow up.
- 493 Footnote: *The random samples were selected from participants who provided serum
- 494 samples at these five timepoints: year 1 day 0, day 30 and day 182, and year 2 day 0 and day
- 495 30.

496

- 497 Figure 2. Antibody titers at various timepoints measured by hemagglutination inhibition
- 498 assay for influenza A(H1N1) and B, and by focus reduction neutralization test for influenza
- 499 A(H3N2). Measured titers are plotted for each group at 0, 30 and 182 days post-vaccination
- 500 of year 1 and at 0 and 30 days post-vaccination of year 2, and lines represent the geometric
- 501 mean titers at each timepoint. Data from group 5, receiving vaccine in both years, are shown
- 502 in red. Data from group 4, receiving placebo in year 1 and vaccine in year 2, are shown in
- 503 blue. Data from the other groups, receiving placebo in both years, are shown in gray.

504

- 505 Figure 3. Antibody levels at various timepoints measured by enzyme-linked immunosorbent
- 506 assay for influenza A(H1N1) and A(H3N2). Measured titers are plotted at 0 and 30 days post-
- 507 vaccination in years 1 and 2, and lines represent the geometric mean antibody levels at each
- 508 timepoint. Data from group 5, receiving vaccine in both years, are shown in red. Data from
- 509 group 4, receiving placebo in year 1 and vaccine in year 2, are shown in blue. Data from the
- 510 other groups, receiving placebo in both years, are shown in gray.

511

513 Table 1. Characteristics of participants randomized to different vaccination strategies

514

- 516 Table 2. Antibody responses to influenza vaccination and placebo in year 2 of the trial, with 95%
- 517 confidence intervals. Antibody responses were measured by HAI for influenza A(H1N1) and B, and
- 518 by FRNT for influenza A(H3N2).

Outcome and Virus	Groups 1-3	Group 4	Group 5	p-value
	$(P-P)$	$(P-V)$	$(V-V)$	comparing
	$(n=15)$	$(n=40)$	$(n=40)$	group $5(V-V)$
				and group 4
				$(P-V)$
Proportion with \geq 4-fold rise in antibody titer from day 0 to day 30 post-vaccination*				
A/Wisconsin/588/2019	13%	78%	45%	0.005
(H1N1)	$(1.6\%, 40\%)$	$(62\%, 89\%)$	$(29\%, 62\%)$	
A/Cambodia/e0826360/2020	0%	60%	53%	0.65
(H3N2)	$(0\%, 21\%)$	$(43\%, 75\%)$	$(36\%, 68\%)$	
B/Washington/02/2019	6.7%	70%	25%	< 0.001
	$(0.2\%, 32\%)$	$(53\%, 83\%)$	$(13\%, 41\%)$	
B/Phuket/3073/2013	0%	68%	10%	< 0.001
	$(0\%, 22\%)$	$(51\%, 81\%)$	$(0.3\%, 24\%)$	

Antibody GMT ratio at day 30 post-vaccination compared to P-P reference group

Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group

(0.55, 1.29)

Proportion with antibody titer ≥*40 at day 30 post-vaccination*

519 *For influenza A(H1N1) and B this was defined as either a pre-vaccination antibody titer <10 and a

520 post-vaccination antibody titre \geq 20, or a pre-vaccination antibody titer \geq 10 and at least a four-fold rise
521 in post-vaccination antibody titer. For influenza A(H3N2) this was defined as either a pre-vaccina

in post-vaccination antibody titer. For influenza A(H3N2) this was defined as either a pre-vaccination

522 antibody titer <20 and a post-vaccination antibody titre \geq 40, or a pre-vaccination antibody titer \geq 20 and at least a four-fold rise in post-vaccination antibody titer.

and at least a four-fold rise in post-vaccination antibody titer.

524 Table 3. Geometric mean antibody levels 30 days post-vaccination for participants receiving

525 vaccination for the first time in the study

- 526 Cells in bold indicate homologous responses to vaccine strains. Values for all three assays are
- 527 antibody titers.
- 528 [‡] This virus contained an egg adaptation, D187V.

529 * The similar virus A/Hong Kong/45/2019 was used in place of A/Minnesota/41/2019 for the FRNT

530 assay

† 531 The similar virus A/Cambodia/e0826360/2020 was used in place of A/Tasmania/503/2020 for the

- 532 FRNT assay
- 533

B/Washington/02/2019 (B/Victoria lineage)

B/Phuket/3073/2013 (B/Yamagata lineage)

